Literature DB >> 9862640

Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals.

C M Hulette1, K A Welsh-Bohmer, M G Murray, A M Saunders, D C Mash, L M McIntyre.   

Abstract

The presence of diffuse or primitive senile plaques in the neocortex of cognitively normal elderly at autopsy has been presumed to represent normal aging. Alternatively, these patients may have developed dementia and clinical Alzheimer disease (AD) if they had survived. In this setting, these patients could be subjects for cognitive or pharmacologic intervention to delay disease onset. We have thus followed a cohort of cognitively normal elderly subjects with a Clinical Dementia Rating (CDR) of 0 at autopsy. Thirty-one brains were examined at postmortem according to Consortium to Establish a Registry for Alzheimer Disease (CERAD) criteria and staged according to Braak. Ten patients were pathologically normal according to CERAD criteria (1a). Two of these patients were Braak Stage II. Seven very elderly subjects exhibited a few primitive neuritic plaques in the cortex and thus represented CERAD 1b. These individuals ranged in age from 85 to 105 years and were thus older than the CERAD la group that ranged in age from 72 to 93. Fourteen patients displayed Possible AD according to CERAD with ages ranging from 66 to 95. Three of these were Braak Stage I, 4 were Braak Stage II, and 7 were Braak Stage III. The Apolipoprotein E4 allele was over-represented in this possible AD group. Neuropsychological data were available on 12 individuals. In these 12 individuals, Possible AD at autopsy could be predicted by cognitive deficits in 1 or more areas including savings scores on memory testing and overall performance on some measures of frontal executive function.

Entities:  

Mesh:

Year:  1998        PMID: 9862640     DOI: 10.1097/00005072-199812000-00009

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  126 in total

Review 1.  Changes in cognition.

Authors:  Marilyn S Albert
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Prescription use disorders in older adults.

Authors:  Raj K Kalapatapu; Maria A Sullivan
Journal:  Am J Addict       Date:  2010-09-21

3.  In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Authors:  Dean F Wong; Paul B Rosenberg; Yun Zhou; Anil Kumar; Vanessa Raymont; Hayden T Ravert; Robert F Dannals; Ayon Nandi; James R Brasić; Weiguo Ye; John Hilton; Constantine Lyketsos; Hank F Kung; Abhinay D Joshi; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  J Nucl Med       Date:  2010-06       Impact factor: 10.057

4.  YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Richard J Perrin; Catherine M Roe; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Mark A Mintun; Elaine R Peskind; Ge Li; Douglas R Galasko; Christopher M Clark; Joseph F Quinn; Gina D'Angelo; James P Malone; R Reid Townsend; John C Morris; Anne M Fagan; David M Holtzman
Journal:  Biol Psychiatry       Date:  2010-11-15       Impact factor: 13.382

Review 5.  Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease.

Authors:  Elizabeth W Twamley; Susan A Legendre Ropacki; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2006-09       Impact factor: 2.892

6.  Factors associated with resistance to dementia despite high Alzheimer disease pathology.

Authors:  D Erten-Lyons; R L Woltjer; H Dodge; R Nixon; R Vorobik; J F Calvert; M Leahy; T Montine; J Kaye
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

Review 7.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 8.  Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B.

Authors:  Keith A Johnson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

9.  Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.

Authors:  John S K Kauwe; Jun Wang; Kevin Mayo; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  Neurogenetics       Date:  2008-09-24       Impact factor: 2.660

10.  Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls.

Authors:  Thomas J Esparza; Hanzhi Zhao; John R Cirrito; Nigel J Cairns; Randall J Bateman; David M Holtzman; David L Brody
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.